Truist raised the firm’s price target on Encompass Health to $86 from $82 and keeps a Buy rating on the shares. The company reported a “strong” Q4, marked by revenue and adjusted EBITDA beats, ongoing labor improvement and continued robust demand/volume trends, the analyst tells investors in a research note. Encompass Health’s cash flow remains strong, underpinning brisk ongoing expansion activity, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EHC:
- Encompass Health Highlights Adjusted Financial Metrics
- Encompass Health reports results for fourth quarter 2023 and issues 2024 guidance
- Encompass Health sees FY24 adjusted EPS $3.77-$4.06, consensus $3.84
- Encompass Health reports Q4 adjusted EPS 95c, consensus 82c
- Encompass Health assumed with an Outperform at William Blair